Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.